{‘She has zero experience’: this American medical establishment girds for Høeg's appointment at the Food and Drug Administration.

While the US undertakes historic revisions to its immunization schedules, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and public health researcher who initially gained attention by questioning coronavirus vaccines in the global health crisis and has concentrated on alleged fatalities after COVID-19 immunization in her short position at the Food and Drug Administration.

Proposed Changes to Pediatric Immunization Schedule

Agency leaders planned to announce major changes to the childhood vaccination calendar in December, bringing the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US out of alignment with much of the international standard with no evidence for benefit. The announcement has been delayed until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the event. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to run the division this calendar year.

A New Direction at the Agency

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad consolidate power at the agency – and it points to a renewed priority upon reevaluating already-approved immunizations at the FDA.

Høeg has often pushed for halting certain pediatric immunization guidelines in the US so as to align more similar to the Danish model, a country with universal health coverage and a population about the population of Wisconsin’s.

So far comments, she has kept her attention on vaccination policy – typically the responsibility of Dr. Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Background

Høeg has little discernible track record in drug development, regulation or administrative roles, which has been customary for previous leaders of the CBER. She has served at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in managing a major agency. She has no expertise in industry regulation.”

Former directors of the center would “be deeply familiar with regulatory frameworks and the science of medication creation”, said Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who headed CBER have had.”

The drug center has an immense workload at the FDA, she pointed out.

“The public just pays attention on the novel medication approvals, but the generic drug division approves numerous off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and other areas, and all of those must be supervised,” she noted. “The thing you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a major leadership component to the job, which manages in excess of 5,000 staff members. “It’s a massive management job, if you perform it correctly,” the former official said.

Agency Reaction and Controversial Policies

Regarding questions about Høeg’s fitness for the role and whether this selection indicates more teamwork among agency officials on immunizations, a representative said that the “concerns are based on inaccurate premises”.

“Her experience is consistent with the responsibilities of her job,” the representative explained, citing the months Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg inherits the agency head's recently launched fast-track approval initiative, a disputed rapid therapy clearance system that apparently troubled her predecessors. “How are these medications being chosen for this voucher program? Who makes the decisions?” Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

Overall, he remarked, “the agency looks to be trending towards more relaxed regulations of most medications, except for shots.”

Established Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if troubling, track record, critics said. She authored a study using unverified volunteer-provided data to determine the incidence of heart inflammation after COVID-19 immunization. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are riskier than they are.

Included in her “wish list” for the incoming federal leadership featured changing guidelines for new vaccines and discontinuing “unnecessary” immunizations, she said after the election on a podcast. At the agency, Dr. Høeg has reportedly suggested preventing teenage boys from obtaining Covid vaccines.

“She’s an complete ideologue who commences with her preconceived notions and reverse-engineers to fit the evidence in a extremely deceptive, fraudulent fashion,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg joined fellow contrarians, {like|